Changes in Seroprevalence and Wellness Over Time in Healthcare Workers (CONSERVE-HCW)
CONSERVE-HCW
1 other identifier
observational
2,000
1 country
1
Brief Summary
The Investigators propose a multi-center, observational, longitudinal, cohort study of the serology and wellness of HCWs over a year of the COVID-19 pandemic.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 10, 2020
CompletedStudy Start
First participant enrolled
June 10, 2020
CompletedFirst Posted
Study publicly available on registry
October 20, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2021
CompletedOctober 20, 2020
October 1, 2020
1.1 years
June 10, 2020
October 19, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Baseline IgG Assay Information
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in HCWs
Baseline
Change in IgG Assay Information
The change in the seroprevalence of anti-SARS-CoV-2 IgG antibodies in HCWs over one year.
From Baseline to 3 months, 6 months, 9 months, & 12 months
Compare seroprevalence of anti-SARS-CoV-2 IgG antibodies between groups
Compare seroprevalence of anti-SARS-CoV-2 IgG antibodies in 'front-line' workers and non-'front-line' HCWs
From Baseline to 3 months, 6 months, 9 months, & 12 months
Impact of COVID-19 Pandemic on Perceived Wellness and Job Satisfaction
Over the 12 months of the study, evaluate the impact of the COVID-19 pandemic on HCW wellness using the Perceived Wellness Survey. Job satisfaction will be measured using a locally developed questionnaire.
Baseline to 12 months
Eligibility Criteria
Study participants will be enrolled across CommonSpirit Health hospitals and care facilities (all branded as Dignity Health) at five sites in Maricopa County, Arizona: Arizona General Hospital, Chandler Regional Medical Center, Mercy Gilbert Medical Center, St. Joseph's Hospital and Medical Center and St. Joseph's Westgate Medical Center.
You may qualify if:
- Age greater than or equal to 18 years; and
- Be an active member of the CommonSpirit Health workforce or medical staff during the COVID-19 pandemic and at the time of enrollment; and
- Have access to the Internet; and
- The ability to provide informed consent.
You may not qualify if:
- Subjects that lack the ability for longitudinal follow-up; and/or
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Brian Tiffany, MDlead
- Chandler Regional Medical Centercollaborator
- Arizona General Hospitalcollaborator
- Mercy Gilbert Medical Centercollaborator
Study Sites (1)
Chandler Regional Medical Center
Chandler, Arizona, 85224, United States
Related Links
Biospecimen
One tube of blood will be sent to the appropriate hospital lab for the Abbott IgG testing. The other two tubes of blood will be processed and biobanked. The same tubes will be drawn on the subsequent visits.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Brian Tiffany, MD, PhD
Chief Medical Officer Dignity Health Arizona
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Chief Medical Officer
Study Record Dates
First Submitted
June 10, 2020
First Posted
October 20, 2020
Study Start
June 10, 2020
Primary Completion
June 30, 2021
Study Completion
December 30, 2021
Last Updated
October 20, 2020
Record last verified: 2020-10